204 related articles for article (PubMed ID: 34195008)
1. Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term.
Andereggen L; Frey J; Andres RH; Luedi MM; Gralla J; Schubert GA; Beck J; Mariani L; Christ E
J Clin Transl Endocrinol; 2021 Mar; 24():100258. PubMed ID: 34195008
[TBL] [Abstract][Full Text] [Related]
2. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
World Neurosurg; 2017 Jan; 97():595-602. PubMed ID: 27773859
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas in adolescent and elderly patients-A comparative long-term analysis.
Andereggen L; Tortora A; Schubert GA; Musahl C; Frey J; Luedi MM; Mariani L; Beck J; Christ E
Front Surg; 2023; 10():967407. PubMed ID: 36814862
[TBL] [Abstract][Full Text] [Related]
5. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
dos Santos Silva CM; Barbosa FR; Lima GA; Warszawski L; Fontes R; Domingues RC; Gadelha MR
Obesity (Silver Spring); 2011 Apr; 19(4):800-5. PubMed ID: 20559294
[TBL] [Abstract][Full Text] [Related]
6. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
Park JY; Choi W; Hong AR; Yoon JH; Kim HK; Jang WY; Jung S; Kang HC
Pituitary; 2021 Dec; 24(6):955-963. PubMed ID: 34189717
[TBL] [Abstract][Full Text] [Related]
7. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.
Zielinski G; Ozdarski M; Maksymowicz M; Szamotulska K; Witek P
Front Endocrinol (Lausanne); 2020; 11():439. PubMed ID: 32733387
[No Abstract] [Full Text] [Related]
8. Surgery for prolactinomas: a better choice?
Honegger J; Nasi-Kordhishti I; Aboutaha N; Giese S
Pituitary; 2020 Feb; 23(1):45-51. PubMed ID: 31853793
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
Wei L; Wei X
Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
[TBL] [Abstract][Full Text] [Related]
10. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
11. Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
Aboelnaga MM; Eladawy EH; Elshafei MM; Abdullah N; Shaer ME
Endocr Metab Immune Disord Drug Targets; 2019; 19(4):511-518. PubMed ID: 30806330
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
13. Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma.
Khalil G; Khan FA; Jamal QM; Saleem A; Masroor H; Abbas K
Cureus; 2021 Sep; 13(9):e17824. PubMed ID: 34660034
[TBL] [Abstract][Full Text] [Related]
14. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
[TBL] [Abstract][Full Text] [Related]
15. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
Berinder K; Nyström T; Höybye C; Hall K; Hulting AL
Pituitary; 2011 Sep; 14(3):199-207. PubMed ID: 21128120
[TBL] [Abstract][Full Text] [Related]
16. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.
Babey M; Sahli R; Vajtai I; Andres RH; Seiler RW
Pituitary; 2011 Sep; 14(3):222-30. PubMed ID: 21170594
[TBL] [Abstract][Full Text] [Related]
17. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?
Perić B; Kruljac I; Šundalić S; Pećina HI; Jović A; Štefanović M; Butorac D; Vrkljan M
Endocr Res; 2016 Aug; 41(3):200-6. PubMed ID: 26864960
[TBL] [Abstract][Full Text] [Related]
18. Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment.
Ali M; Mirza L
AACE Clin Case Rep; 2021; 7(3):204-206. PubMed ID: 34095489
[TBL] [Abstract][Full Text] [Related]
19. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline.
Pala NA; Laway BA; Misgar RA; Dar RA
Diabetol Metab Syndr; 2015; 7():99. PubMed ID: 26583049
[TBL] [Abstract][Full Text] [Related]
20. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.
Hoffmann A; Adelmann S; Lohle K; Claviez A; Müller HL
Eur J Pediatr; 2018 Jan; 177(1):125-132. PubMed ID: 29168011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
